Fermenta Biotech Ltd

The approval enables Indian food and supplement manufacturers to use VITADEE Green in fortified foods, beverages, dietary supplements and nutraceutical products. The company said the approval opens up India's large consumer market for its plant-based Vitamin D3 solution and reinforces its position in science-backed Vitamin D3 products. Fermenta added that the product is protected by an Indian process patent and is developed and manufactured in India. Managing director Prashant Nagre said the approval will allow the company to address the country's widespread Vitamin D deficiency by offering a sustainable, scalable and affordable plant-based Vitamin D3 solution. He added that VITADEE Green supports the government's Make in India initiative by providing a domestically manufactured alternative for Indian formulators. Fermenta Biotech said the approval also provides vegetarian consumers with access to a plant-based Vitamin D3 option and supports the broader objective of addressing Vitamin D deficiency through food fortification. Fermenta Biotech manufactures nutritional ingredients, active pharmaceutical ingredients (APIs), intermediates and nutritional premixes, while also offering green chemistry and environmental solutions. The company operates manufacturing facilities in Himachal Pradesh, Gujarat and Andhra Pradesh, supported by an R&D centre in Thane, and serves more than 400 customers across over 60 countries. On a consolidated basis, Fermenta Biotech's net profit declined 44.20% to Rs 19.19 crore while net sales declined 13.06% to Rs 121.58 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live

Fermenta Biotech announced that its Vitamin D3 (Cholecalciferol) - Plant Source (VITADEE Green') has received approval from the Food Safety and Standards Authority of India (FSSAI) for use as an ingredient in Health Supplements, Nutraceuticals and Food Products. The approval allows Indian food and supplement manufacturers to use VITADEE Green' in fortified staple foods, food and beverages, dietary supplements and nutraceuticals, addressing one of the most pressing gaps in the country's nutritional landscape. Studies estimate that a large percentage of the Indian population has suboptimal Vitamin D levels, a deficiency increasingly linked to urbanisation, indoor lifestyles and limited sun exposure despite the country's geography.

Fermenta Biotech Ltd gained 3.48% today to trade at Rs 364. The BSE Healthcare index is up 0.27% to quote at 48662.27. The index is up 2.48 % over last one month. Among the other constituents of the index, Viyash Scientific Ltd increased 3.4% and IOL Chemicals & Pharmaceuticals Ltd added 2.97% on the day. The BSE Healthcare index went up 12.87 % over last one year compared to the 7.1% fall in benchmark SENSEX. Fermenta Biotech Ltd has added 20.53% over last one month compared to 2.48% gain in BSE Healthcare index and 0.34% drop in the SENSEX. On the BSE, 3231 shares were traded in the counter so far compared with average daily volumes of 11042 shares in the past one month. The stock hit a record high of Rs 399 on 14 Jul 2025. The stock hit a 52-week low of Rs 256.4 on 05 Dec 2025.Powered by Capital Market - Live

Fermenta Biotech announced that the 74th Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Fermenta Biotech announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 3.75 per equity Share (i.e. 75%) , subject to the approval of the shareholders.

Net profit of Fermenta Biotech declined 44.20% to Rs 19.19 crore in the quarter ended March 2026 as against Rs 34.39 crore during the previous quarter ended March 2025. Sales declined 13.06% to Rs 121.58 crore in the quarter ended March 2026 as against Rs 139.85 crore during the previous quarter ended March 2025. For the full year,net profit declined 6.62% to Rs 71.77 crore in the year ended March 2026 as against Rs 76.86 crore during the previous year ended March 2025. Sales rose 11.92% to Rs 525.43 crore in the year ended March 2026 as against Rs 469.48 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales121.58139.85 -13 525.43469.48 12 OPM %16.4526.42 -19.0023.39 - PBDT22.2537.85 -41 110.68107.43 3 PBT17.1431.98 -46 88.9883.21 7 NP19.1934.39 -44 71.7776.86 -7 Powered by Capital Market - Live

Fermenta Biotech will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Net profit of Fermenta Biotech declined 65.65% to Rs 12.68 crore in the quarter ended December 2025 as against Rs 36.91 crore during the previous quarter ended December 2024. Sales declined 12.21% to Rs 137.36 crore in the quarter ended December 2025 as against Rs 156.47 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales137.36156.47 -12 OPM %18.1834.04 - PBDT25.0551.42 -51 PBT19.6845.34 -57 NP12.6836.91 -66 Powered by Capital Market - Live

Fermenta Biotech will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

Fermenta Biotech will hold a meeting of the Board of Directors of the Company on 10 December 2025.Powered by Capital Market - Live